UNSPSC 51332831: Trifluoperazine

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C21H24F3N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 214IZI85K3, chemically known as 10h-phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- but generally known as trifluoperazine, which bears US NIH Compound Identifier 5566. European Medicines Agency schedules Trifluoperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11288MIG.

UNSPSC 51332831 Trifluoperazine, a Commodity code, nominally identifies a specific antipsychotic pharmaceutical, but recent state and local procurement activity under this code does not reflect purchases of trifluoperazine itself. Instead, the code appears to be misaligned with the opportunities actually posted against it, which center on naloxone, safe drug deactivation systems, and broader pharmaceutical supply arrangements. State and local governments are using this code—or the code is being applied—to procure emergency medication kits, pharmacy benefit program services, and generic pharmaceutical and over-the-counter product distribution networks. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances serving state agencies and local government facilities. The scope of work involves competitive supply arrangements with quarterly or ongoing delivery requirements, compliance with federal drug-supply chain security standards, manufacturing-practice certifications, and wholesaler relationships with chargeback and electronic data interchange capabilities.

Activity appears concentrated in Florida and the Upper Midwest and Texas. Seminole County, Florida issued IFB60459723LAS on June 30, 2026 (response due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring vendors to include shipping costs and comply with E-Verify and drug-free workplace certification. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, seeking information on direct contracting capacity outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers and meet cGMP, DSCSA compliance, and $5 million commercial general liability insurance. The code shows active procurement in pharmaceutical supply and emergency response medication but the close mismatch between the nominal code name and recent opportunity content suggests either a tagging error or a broad-scope application of this commodity code to cover pharmaceuticals beyond trifluoperazine.